TN2009000050A1 - Production method of methane gas from olive mill waste - Google Patents
Production method of methane gas from olive mill wasteInfo
- Publication number
- TN2009000050A1 TN2009000050A1 TN2009000050A TN2009000050A TN2009000050A1 TN 2009000050 A1 TN2009000050 A1 TN 2009000050A1 TN 2009000050 A TN2009000050 A TN 2009000050A TN 2009000050 A TN2009000050 A TN 2009000050A TN 2009000050 A1 TN2009000050 A1 TN 2009000050A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methane gas
- olive mill
- mill wastewater
- secondary sludge
- sludge
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82516806P | 2006-09-11 | 2006-09-11 | |
PCT/KR2006/005503 WO2008038860A1 (fr) | 2006-09-26 | 2006-12-15 | Procédé de production du méthane à partir de déchets d'olives |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2009000050A1 true TN2009000050A1 (en) | 2010-08-19 |
Family
ID=39032357
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TN2009000049A TN2009000049A1 (en) | 2006-09-11 | 2009-02-17 | A pyrrolopyrazin as syk-kinase inhibitor |
TN2009000050A TN2009000050A1 (en) | 2006-09-11 | 2009-02-17 | Production method of methane gas from olive mill waste |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TN2009000049A TN2009000049A1 (en) | 2006-09-11 | 2009-02-17 | A pyrrolopyrazin as syk-kinase inhibitor |
Country Status (32)
Country | Link |
---|---|
US (2) | US8658649B2 (fr) |
EP (1) | EP2094708B1 (fr) |
JP (1) | JP5161237B2 (fr) |
KR (1) | KR101443056B1 (fr) |
CN (2) | CN103804383A (fr) |
AR (1) | AR062745A1 (fr) |
AU (1) | AU2007296592B8 (fr) |
BR (1) | BRPI0716781A2 (fr) |
CA (1) | CA2663175C (fr) |
CL (1) | CL2007002617A1 (fr) |
CO (1) | CO6160236A2 (fr) |
CR (1) | CR10636A (fr) |
DK (1) | DK2094708T3 (fr) |
ES (1) | ES2437318T3 (fr) |
GT (1) | GT200900055A (fr) |
HN (1) | HN2009000455A (fr) |
IL (1) | IL197381A (fr) |
MA (1) | MA30781B1 (fr) |
MX (1) | MX2009002616A (fr) |
MY (1) | MY148107A (fr) |
NI (1) | NI200900021A (fr) |
NO (1) | NO20091265L (fr) |
NZ (1) | NZ575496A (fr) |
PE (1) | PE20081372A1 (fr) |
PT (1) | PT2094708E (fr) |
RU (1) | RU2440352C2 (fr) |
TN (2) | TN2009000049A1 (fr) |
TW (1) | TWI399379B (fr) |
UA (1) | UA94622C2 (fr) |
UY (1) | UY30584A1 (fr) |
WO (1) | WO2008033798A2 (fr) |
ZA (1) | ZA200901073B (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2247592T3 (da) | 2008-02-25 | 2011-09-26 | Hoffmann La Roche | Pyrrolopyrazinkinaseinhibitors |
PT2250172E (pt) | 2008-02-25 | 2011-11-30 | Hoffmann La Roche | Inibidores de pirrolpirazina-cinase |
WO2009106441A1 (fr) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Inhibiteurs de la pyrrolopyrazine kinase |
CA2716223A1 (fr) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Inhibiteurs de kinase pyrrolopyrazine |
WO2009106444A1 (fr) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Inhibiteurs de kinase pyrrolopyrazine |
BRPI0909659A2 (pt) * | 2008-03-10 | 2015-09-22 | Sanofi Aventis | tratamento para distúrbios relacionados oculares |
FR2929851B1 (fr) * | 2008-04-09 | 2012-11-30 | Centre Nat Rech Scient | Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules |
PA8851701A1 (es) | 2008-12-03 | 2010-07-27 | Sanofi Aventis | Tratamiento para la glomerulonefritis |
KR20110108334A (ko) | 2008-12-04 | 2011-10-05 | 사노피 | 결정질 형태 |
TW201034675A (en) * | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
US20110112101A1 (en) * | 2009-03-05 | 2011-05-12 | Sanofi-Aventis | Treatment for ocular-related disorders |
AR075869A1 (es) * | 2009-03-19 | 2011-05-04 | Sanofi Aventis | Sintesis de azaindoles |
CA2786950C (fr) | 2009-12-23 | 2019-01-15 | Takeda Pharmaceutical Company Limited | Pyrrolidinones accoles en tant d'inhibiteurs de syk |
US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US8481541B2 (en) * | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
CN103003281A (zh) * | 2010-05-20 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为JAK和SYK抑制剂的吡咯并[2,3-b]吡嗪-7-甲酰胺衍生物和它们的用途 |
KR20130083387A (ko) | 2010-05-20 | 2013-07-22 | 에프. 호프만-라 로슈 아게 | Syk 및 jak 억제제로서 피롤로피라진 유도체 |
EP2441755A1 (fr) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Dérivés de pyridine et isoquinoline comme inhibiteurs des kinases Syk et JAK |
EP2489663A1 (fr) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Composés en tant qu'inhibiteurs de la syk kinase |
JP6026525B2 (ja) | 2011-06-22 | 2016-11-16 | 武田薬品工業株式会社 | 置換6−アザ−イソインドリン−1−オン誘導体 |
EP2888262B1 (fr) * | 2012-08-21 | 2018-12-19 | F.Hoffmann-La Roche Ag | Pyrrolo[2,3-b]pyrazines en tant qu' inhibiteurs de syk |
WO2015017610A1 (fr) * | 2013-07-31 | 2015-02-05 | Gilead Sciences, Inc. | Inhibiteurs syk |
BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
CN116969927B (zh) * | 2023-06-07 | 2024-03-19 | 中南民族大学 | 一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1141949A (en) | 1966-02-23 | 1969-02-05 | Sterling Drug Inc | 7-azaindole derivatives |
US3992392A (en) | 1973-04-27 | 1976-11-16 | The Ohio State University Research Foundation | Synthesis of indoles from anilines and intermediates therein |
SE9100920D0 (sv) | 1991-03-27 | 1991-03-27 | Astra Ab | New active compounds |
US6075037A (en) | 1994-06-09 | 2000-06-13 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
FR2732969B1 (fr) | 1995-04-14 | 1997-05-16 | Adir | Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2001506980A (ja) | 1996-11-19 | 2001-05-29 | アムジエン・インコーポレーテツド | アリールおよびヘテロアリール置換縮合ピロール抗炎症剤 |
US6312835B1 (en) | 1997-02-13 | 2001-11-06 | Queen's University At Kingston | Luminescent compounds and methods of making and using same |
WO1998041525A1 (fr) | 1997-03-19 | 1998-09-24 | Basf Aktiengesellschaft | Pyrrolo [2,3] pyrimidines et leur utilisation comme inhibiteurs de la tyrosine kinase |
WO1998047899A1 (fr) | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Pyrrolopyridines substituees utilisees dans le traitement des maladies inflammatoires |
HUP0002956A3 (en) | 1997-08-05 | 2002-01-28 | Pfizer Prod Inc | Use of 4-aminopyrrole[3,2d]pyrimidines for the preparation of pharmaceutical compositions treating diseases related to an excess of neuropeptide y |
YU22000A (sh) | 1997-10-20 | 2003-01-31 | F. Hoffmann-La Roche Ag. | Biciklični inhibitori kinaze |
AU767599B2 (en) | 1998-03-06 | 2003-11-20 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
AU3210799A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
CA2326140A1 (fr) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonistes de l'hormone liberant la gonadotropine (gnrh) |
DE69942801D1 (de) | 1998-05-26 | 2010-11-11 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
TR200101395T2 (tr) | 1998-09-18 | 2001-11-21 | Basf Ag. | Kinaz engelleyiciler olarak 4-Aminopyrrolopyrimidin'ler |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
GB9930698D0 (en) * | 1999-12-24 | 2000-02-16 | Rhone Poulenc Rorer Ltd | Chemical compounds |
CA2699568C (fr) * | 1999-12-24 | 2013-03-12 | Aventis Pharma Limited | Azaindoles |
US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
DE10009000A1 (de) | 2000-02-25 | 2001-08-30 | Basf Ag | Verfahren zur Herstellung substituierter Indole |
EP1265897A1 (fr) | 2000-03-20 | 2002-12-18 | Axys Pharmaceuticals, Inc. | Inhibiteurs de la protease exempte d'amidine |
JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
US6673923B2 (en) | 2000-05-03 | 2004-01-06 | Tularik Inc. | Pyrazole antimicrobial agents |
WO2001096336A2 (fr) | 2000-06-14 | 2001-12-20 | Warner-Lambert Company | Heterocyles bicycliques fondus -6,5 |
JP2004510762A (ja) | 2000-10-02 | 2004-04-08 | メルク エンド カムパニー インコーポレーテッド | プレニル−蛋白質トランスフェラーゼの阻害剤 |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
WO2003000690A1 (fr) | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthese de composes heterocycliques faisant appel a une technologie micro-onde |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
US20040082365A1 (en) * | 2002-07-18 | 2004-04-29 | Celerica Ltd | Digitization and transmitting cellular RF signals by several light wavelengths |
EP1388541A1 (fr) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines utilisées comme inhibiteurs de kinases |
WO2005014543A1 (fr) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc |
US7452993B2 (en) * | 2004-07-27 | 2008-11-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
FR2876582B1 (fr) | 2004-10-15 | 2007-01-05 | Centre Nat Rech Scient Cnrse | Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
WO2006052712A1 (fr) | 2004-11-08 | 2006-05-18 | Baxter International Inc. | Compositions nanoparticulaires d'inhibiteurs de la tubuline |
EP1814882A1 (fr) * | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases |
US20110112101A1 (en) | 2009-03-05 | 2011-05-12 | Sanofi-Aventis | Treatment for ocular-related disorders |
-
2007
- 2007-09-10 CL CL200702617A patent/CL2007002617A1/es unknown
- 2007-09-11 TW TW096133786A patent/TWI399379B/zh not_active IP Right Cessation
- 2007-09-11 RU RU2009113615/04A patent/RU2440352C2/ru not_active IP Right Cessation
- 2007-09-11 DK DK07842207.8T patent/DK2094708T3/da active
- 2007-09-11 CA CA2663175A patent/CA2663175C/fr not_active Expired - Fee Related
- 2007-09-11 NZ NZ575496A patent/NZ575496A/en not_active IP Right Cessation
- 2007-09-11 AU AU2007296592A patent/AU2007296592B8/en not_active Ceased
- 2007-09-11 AR ARP070104013A patent/AR062745A1/es not_active Application Discontinuation
- 2007-09-11 PT PT78422078T patent/PT2094708E/pt unknown
- 2007-09-11 PE PE2007001220A patent/PE20081372A1/es not_active Application Discontinuation
- 2007-09-11 UY UY30584A patent/UY30584A1/es not_active Application Discontinuation
- 2007-09-11 BR BRPI0716781-4A2A patent/BRPI0716781A2/pt not_active IP Right Cessation
- 2007-09-11 WO PCT/US2007/078103 patent/WO2008033798A2/fr active Search and Examination
- 2007-09-11 CN CN201310652393.XA patent/CN103804383A/zh active Pending
- 2007-09-11 EP EP07842207.8A patent/EP2094708B1/fr active Active
- 2007-09-11 MY MYPI20090720A patent/MY148107A/en unknown
- 2007-09-11 KR KR1020097005040A patent/KR101443056B1/ko not_active IP Right Cessation
- 2007-09-11 MX MX2009002616A patent/MX2009002616A/es active IP Right Grant
- 2007-09-11 ES ES07842207.8T patent/ES2437318T3/es active Active
- 2007-09-11 CN CNA2007800336608A patent/CN101511838A/zh active Pending
- 2007-09-11 JP JP2009538434A patent/JP5161237B2/ja not_active Expired - Fee Related
- 2007-11-09 UA UAA200903417A patent/UA94622C2/ru unknown
-
2009
- 2009-02-16 ZA ZA2009/01073A patent/ZA200901073B/en unknown
- 2009-02-17 NI NI200900021A patent/NI200900021A/es unknown
- 2009-02-17 TN TN2009000049A patent/TN2009000049A1/fr unknown
- 2009-02-17 TN TN2009000050A patent/TN2009000050A1/fr unknown
- 2009-02-25 CR CR10636A patent/CR10636A/es not_active Application Discontinuation
- 2009-03-03 IL IL197381A patent/IL197381A/en not_active IP Right Cessation
- 2009-03-10 HN HN2009000455A patent/HN2009000455A/es unknown
- 2009-03-10 GT GT200900055A patent/GT200900055A/es unknown
- 2009-03-10 US US12/401,254 patent/US8658649B2/en not_active Expired - Fee Related
- 2009-03-11 CO CO09025278A patent/CO6160236A2/es unknown
- 2009-03-26 NO NO20091265A patent/NO20091265L/no not_active Application Discontinuation
- 2009-04-06 MA MA31765A patent/MA30781B1/fr unknown
-
2014
- 2014-01-28 US US14/166,396 patent/US20140142110A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2009000050A1 (en) | Production method of methane gas from olive mill waste | |
Batstone et al. | The role of anaerobic digestion in the emerging energy economy | |
Cavinato et al. | Optimization of two-phase thermophilic anaerobic digestion of biowaste for hydrogen and methane production through reject water recirculation | |
Abeysiriwardana-Arachchige et al. | Removal and recovery of nutrients from municipal sewage: Algal vs. conventional approaches | |
Wacławek et al. | A novel approach for simultaneous improvement of dewaterability, post-digestion liquor properties and toluene removal from anaerobically digested sludge | |
Yang et al. | Free ammonia-based sludge treatment reduces sludge production in the wastewater treatment process | |
Chaiprapat et al. | Enhancing digestion efficiency of POME in anaerobic sequencing batch reactor with ozonation pretreatment and cycle time reduction | |
WO2010148044A9 (fr) | Procédé pour réduire la génération de boues dans des systèmes de traitement d'eaux résiduaires | |
WO2006128011A3 (fr) | Procede de digestion anaerobie pour des dechets a faible teneur en solides | |
Gottardo et al. | Hydrogen and methane production from biowaste and sewage sludge by two phases anaerobic codigestion | |
Kadam et al. | Realizable wastewater treatment process for carbon neutrality and energy sustainability: A review | |
WO2007048537A8 (fr) | Procede et reacteur pour traitement anaerobique d'eaux usees au moyen d'un uasb | |
Wang et al. | Nitrate addition improves hydrogen production from acidic fermentation of waste activated sludge | |
Mahdy et al. | Response of the microbial community to the methanogenic performance of biologically hydrolyzed sewage sludge with variable hydraulic retention times | |
Demirer et al. | Two-phase thermophilic acidification and mesophilic methanogenesis anaerobic digestion of waste-activated sludge | |
Pedizzi et al. | A combination of ammonia stripping and low temperature thermal pre-treatment improves anaerobic post-digestion of the supernatant from organic fraction of municipal solid waste treatment | |
CA2468158A1 (fr) | Systeme et methode pour la fabrication de biogaz et de compost | |
Liang et al. | Effective methane production from waste activated sludge in anaerobic digestion via formic acid pretreatment | |
Yin et al. | Application and improvement methods of sludge alkaline fermentation liquid as a carbon source for biological nutrient removal: a review | |
Isa et al. | Anaerobic treatment of ultrasound pretreated palm oil mill effluent (POME): microbial diversity and enhancement of biogas production | |
Bonu et al. | Impact of thermal pre-treatment on anaerobic co-digestion of sewage sludge and landfill leachate | |
Park et al. | Comparison methane production potential between granular and suspended sludge at varying ammonia concentration | |
Li et al. | Nitrogen removal of thermal hydrolysis-anaerobic digestion liquid: A review | |
Balasundaram et al. | Advanced steam explosion as thermal hydrolysis process for high solids anaerobic digestion and enhanced methane yield: proof of concept | |
Tang et al. | Freezing method assists calcium hypochlorite for synergistically promoting methane production from sludge anaerobic digestion |